Walleye Capital’s Amicus Therapeutics FOLD Stock Holding History

Walleye Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,500	Closed	-$78.3K	–	4590
2025 Q4	$78.3K	Sell	5,500 -16,600	-75%	-$163K	﹤0.01%	3952
2025 Q3	$174K	Buy	22,100 +6,900	+45%	+$49.1K	﹤0.01%	3410
2025 Q2	$87.1K	Buy	+15,200	New	+$98.1K	﹤0.01%	3836
2025 Q1	–	Sell	-18,600	Closed	-$175K	–	4524
2024 Q4	$175K	Sell	18,600 -16,000	-46%	-$166K	﹤0.01%	3849
2024 Q3	$370K	Buy	34,600 +19,000	+122%	+$207K	﹤0.01%	3570
2024 Q2	$155K	Buy	15,600 +1,100	+8%	+$11.3K	﹤0.01%	4469
2024 Q1	$171K	Buy	+14,500	New	+$185K	﹤0.01%	4075
2023 Q4	–	Sell	-600	Closed	-$7.3K	–	5134
2023 Q3	$7.3K	Buy	+600	New	+$7.74K	﹤0.01%	4529
2019 Q3	–	Sell	-2,400	Closed	-$30K	–	2013
2019 Q2	$30K	Sell	2,400 -6,500	-73%	-$82.5K	﹤0.01%	1471
2019 Q1	$121K	Buy	+8,900	New	+$109K	0.02%	979

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Walleye Capital's FOLD Position: Q2 2026 in Review

Walleye Capital sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 15,399 shares — an estimated $223K sold.

Walleye Capital first reported a position in FOLD in Q1 2019 and held it in 12 quarters. The position peaked at $4.32M in Q3 2024. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Walleye Capital reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Walleye Capital sold 15,399 Amicus Therapeutics shares in Q2 2026, an estimated $223K.
Walleye Capital first reported a position in Amicus Therapeutics in Q1 2019 and held it in 12 quarters.
Walleye Capital's Amicus Therapeutics position peaked at $4.32M in Q3 2024.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.